obesity treatment with bariatric surgery vs glp-1 receptor agonists Cost effectiveness of s vs. ESG vs. Bariatric Surgery vs.

Pacheco-Pantoja, E

(2024) 385:q1448

By analyzing the reported adverse events in the US Food and Drug Administrations database, Elashoff reported that treatment with DPP4 inhibitor sitagliptin or GLP-1R agonist exenatide increased the risk of pancreatitis and pancreatic cancer as compared with other therapies

Y.HuangJ

At normal levels, the GLP-1R is not stimulated by structurally identical peptides such as GCG, GCG like peptide 2 (GLP-2), or GLP-1 breakdown products [25]

A comprehensive approach may include both strategies: dietary optimization with low-glycemic sweeteners alongside pharmacological support when indicated